ATEC · Alphatec Holdings, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. ATEC delivered Q2 revenue of $214M (up 15%) with surgical revenue up 17% on 20% case volume growth, raised full-year adjusted EBITDA guidance to ~$140M from ~$134M, while reaffirming revenue (~$882M) and free cash flow (≥$20M) outlook; revenue per case guidance moved from flattish to down low single digits as biologics attach rate only stabilized.
- + Q2 surgical revenue grew 17% to $196M on 20% case volume growth and 24% net new surgeon user growth.
- + Raised full-year 2026 adjusted EBITDA guidance to ~$140M from prior ~$134M.
- + Gross margin expanded 260 bps year-over-year to 72.5%, with operating expenses improving ~260 bps as a percentage of revenue.
- + Refinancing extends maturities to 2031 and is expected to reduce annual interest expense by more than $6M.
- + EOS Insight adoption driving ~32% implant revenue lift per surgeon within six months of Go-Live.
- − Full-year revenue per case guidance lowered from flattish to down low single digits as biologics attach only stabilized rather than improved.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATEC
this stock
Alphatec Holdings, Inc.
|
$1.59B | -52.3% | -15.4% | — | 9.3% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATEC | -0.9% | +7.5% | -10.8% | -2.8% | -52.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -0.7% | +8.0% | -23.0% | -3.7% | -65.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.